Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 9.80
KBIO's Cash to Debt is ranked higher than
78% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. KBIO: 9.80 )
Ranked among companies with meaningful Cash to Debt only.
KBIO' s Cash to Debt Range Over the Past 10 Years
Min: 1.07  Med: 7.7 Max: No Debt
Current: 9.8
F-Score: 1
Z-Score: -29.25
M-Score: -6.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -754.30
KBIO's ROE (%) is ranked lower than
95% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. KBIO: -754.30 )
Ranked among companies with meaningful ROE (%) only.
KBIO' s ROE (%) Range Over the Past 10 Years
Min: -754.3  Med: -161.21 Max: -89.25
Current: -754.3
-754.3
-89.25
ROA (%) -249.07
KBIO's ROA (%) is ranked lower than
92% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. KBIO: -249.07 )
Ranked among companies with meaningful ROA (%) only.
KBIO' s ROA (%) Range Over the Past 10 Years
Min: -249.07  Med: -81.26 Max: -23.07
Current: -249.07
-249.07
-23.07
ROC (Joel Greenblatt) (%) -2589.98
KBIO's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. KBIO: -2589.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KBIO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -16150.99  Med: -7100.46 Max: -1045.43
Current: -2589.98
-16150.99
-1045.43
Revenue Growth (3Y)(%) -100.00
KBIO's Revenue Growth (3Y)(%) is ranked lower than
100% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. KBIO: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KBIO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: -94.4
Current: -100
EBITDA Growth (3Y)(%) -54.40
KBIO's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. KBIO: -54.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KBIO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -36.65 Max: 9.4
Current: -54.4
0
9.4
EPS Growth (3Y)(%) -54.30
KBIO's EPS Growth (3Y)(%) is ranked lower than
94% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. KBIO: -54.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KBIO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -35.6 Max: 0.1
Current: -54.3
0
0.1
» KBIO's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with KBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MTP, OTCPK:PTIX, OTCPK:DYAI, NAS:VSTM, NAS:RPRX, OTCPK:IGXT, OTCPK:NURPF, OTCPK:DMYDY, NAS:NVET, AMEX:IBIO, OTCPK:MTFBF, NAS:CYTR, AMEX:PLX, OTCPK:AQBT, NAS:OCRX, NAS:CNAT, AMEX:RNN, NAS:DNAI, NAS:GLMD, OTCPK:ORGS » details
Traded in other countries:0KB1.Germany,
KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.

KaloBios Pharmaceuticals Inc. was incorporated on March 15, 2000. On February 5, 2013 the Company closed its initial public offering. The Company is a biopharmaceutical company engaged on the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families. With Humaneered antibody technology, the Company produced a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a clinical focus on respiratory diseases and cancer. Humaneered antibodies have tested clinically in over 250 patients with no evidence of immunogenicity. The Company identifies and develops products that treat multiple indications through proof-of-concept studies. The Company has advanced three antibodies to the clinical development stage: KB001-A, for the treatment of Pa VAP; KB004, for hematologic malignancies; and KB003, for severe asthma. KB001-A, is a Humaneered, recombinant, PEGylated, anti-Pseudomonas PcrV high-affinity Fab antibody that is being developed for the prevention and treatment of infections by Pa, a gram negative bacteria that can cause pneumonia in mechanically ventilated patients and chronic respiratory infections in individuals with CF. KB004 is a Humaneered, monoclonal antibody in which the carbohydrate chains lack fucose, thereby enhancing the targeted cell-killing activity of the antibody. KB003 is a Humaneered, recombinant monoclonal antibody that targets and neutralizes human granulocyte macrophage colony-stimulating factor, or GM-CSF, with potential for use in inflammatory, autoimmune and other indications. Humaneered technology platform addresses issues of therapeutic antibody engineering and down-stream processing issues. The Humaneered technology is a method for converting antibodies into engineered human antibodies designed for therapeutic use, particularly for chronic conditions. The technology is designed to produce antibodies that have specificity and affinity for their target antigen, low propensity for aggregation, and a long-term stability. KB001-A, KB003, and KB004 are all Humaneered antibodies or antibody fragments. The Company currently has a collaboration with Sanofi for the development of KB001-A, and have licensed its Humaneered technology non-exclusively to Novartis and also in-licensed certain rights from, among others, UCSF and LICR. The Company owns 12 issued U.S. patents, with another issued U.S. patent owned jointly with a third party. It has an exclusive license to seven U.S. patents and owns 49 issued foreign patents. The Company's competitors include pharmaceutical companies, biotechnology companies, academic institutions, and other research organizations. The Company also competes with Valneva, MedImmune, Micromet along with Nycomed among others.

Ratios

vs
industry
vs
history
P/B 4.05
KBIO's P/B is ranked higher than
65% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. KBIO: 4.05 )
Ranked among companies with meaningful P/B only.
KBIO' s P/B Range Over the Past 10 Years
Min: 0.11  Med: 1.46 Max: 4.25
Current: 4.05
0.11
4.25
EV-to-EBIT -1.23
KBIO's EV-to-EBIT is ranked lower than
99.99% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. KBIO: -1.23 )
Ranked among companies with meaningful EV-to-EBIT only.
KBIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.9  Med: -0.2 Max: 0.9
Current: -1.23
-2.9
0.9
EV-to-EBITDA -1.24
KBIO's EV-to-EBITDA is ranked lower than
99.99% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. KBIO: -1.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
KBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.9  Med: -0.2 Max: 0.9
Current: -1.24
-2.9
0.9
Current Ratio 1.61
KBIO's Current Ratio is ranked lower than
99.99% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. KBIO: 1.61 )
Ranked among companies with meaningful Current Ratio only.
KBIO' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 4.72 Max: 11.14
Current: 1.61
1.3
11.14
Quick Ratio 1.61
KBIO's Quick Ratio is ranked lower than
99.99% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. KBIO: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
KBIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.3  Med: 4.72 Max: 11.14
Current: 1.61
1.3
11.14

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -157.10
KBIO's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. KBIO: -157.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KBIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -169.3  Med: -157.2 Max: 0
Current: -157.1
-169.3
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.57
KBIO's Price/Net Cash is ranked higher than
57% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. KBIO: 6.57 )
Ranked among companies with meaningful Price/Net Cash only.
KBIO' s Price/Net Cash Range Over the Past 10 Years
Min: 1.12  Med: 2.5 Max: 34.69
Current: 6.57
1.12
34.69
Price/Net Current Asset Value 4.28
KBIO's Price/Net Current Asset Value is ranked higher than
76% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. KBIO: 4.28 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KBIO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.05  Med: 2.41 Max: 299.5
Current: 4.28
1.05
299.5
Price/Tangible Book 4.05
KBIO's Price/Tangible Book is ranked higher than
72% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. KBIO: 4.05 )
Ranked among companies with meaningful Price/Tangible Book only.
KBIO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1  Med: 2.36 Max: 86.81
Current: 4.05
1
86.81
Earnings Yield (Greenblatt) (%) -81.30
KBIO's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. KBIO: -81.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KBIO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -81.3  Med: 170.55 Max: 269.1
Current: -81.3
-81.3
269.1

More Statistics

EPS (TTM) $ -8.62
Beta3.26
Short Percentage of Float8.17%
52-Week Range $0.44 - 45.82
Shares Outstanding (Mil)14.90

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -2.26
EPS w/o NRI ($) -2.26
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for KBIO

Headlines

Articles On GuruFocus.com
Insiders Sell Paycom, Facebook and Virtu Financial, Buy KaloBios Nov 20 2015 

More From Other Websites
4:48 pm KaloBios Pharma confirms it is now current on SEC periodic filings (filed outstanding... Sep 25 2016
KaloBios Now Current on SEC Periodic Filings Sep 23 2016
KaloBios reports 1Q loss Sep 23 2016
KaloBios reports 1Q loss Sep 23 2016
KaloBios reports 2Q loss Sep 23 2016
KaloBios reports 2Q loss Sep 23 2016
KaleBios says it's current on its financials after 10-Q filing Sep 23 2016
KaloBios Now Current on SEC Periodic Filings Sep 23 2016
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Sep 23 2016
The day I met Martin Shkreli: Inside the biotech-saving deal for a tropical disease drug Sep 20 2016
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 19 2016
KaloBios Plans Big In The Post-Shkreli Era (KBIO) Sep 13 2016
KALOBIOS PHARMACEUTICALS INC Financials Sep 07 2016
KaloBios Files Outstanding 10-Q and 10-K for 2015 Sep 02 2016
KaloBios files outstanding 10-Q and 10-K for 2015 Sep 02 2016
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Sep 01 2016
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 31 2016
Martin Shkreli Sells All His Shares in Kalobios Pharmaceuticals Inc (KBIO) Aug 29 2016
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 29 2016
KaloBios Announces Martin Shkreli's Sale of His Stake in the Company Aug 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)